The Efficiency and Toxicity OfAnlotinib in Combination With Docetaxel Followed by Epirubicin and Cyclophosphamide Regimen as Neoadjuvant Treatment in IIB to IIIA Triple Negative Breast Cancer: A Single-Arm, Multicenter, Open-Label, Phase II Study

被引：1

作者：

Chen, Xi ^{[1
]}

Wei, Xinyu ^{[1
]}

Yao, Peizhuo ^{[1
]}

Liu, Yanbin ^{[1
]}

Guan, Haitao ^{[2
]}

Kang, Huafeng ^{[2
]}

Liu, Di ^{[2
]}

Diao, Yan ^{[2
]}

Ma, Xiaobin ^{[2
]}

Min, Weili ^{[2
]}

Shan, Changyou ^{[2
]}

Zhao, Yang ^{[2
]}

Zhao, Fang ^{[2
]}

Chen, Yuanyuan ^{[3
]}

Xiao, Dong ^{[4
]}

She, Qing ^{[3
]}

Liu, Youhuai ^{[3
]}

Zhang, Yinbin ^{[2
]}

Zhang, Shuqun ^{[2
]}

机构：

[1] Xi An Jiao Tong Univ, Xian, Shaanxi, Peoples R China

[2] Xi An Jiao Tong Univ, Affiliated Hosp 2, 157,West 5th Rd, Xian 710004, Shaanxi, Peoples R China

[3] Baoji Cent Hosp Shaanxi Prov, Baoji, Shaanxi, Peoples R China

[4] 3201 Hosp Hanzhong City, Hanzhong, Shaanxi, Peoples R China

来源：

CLINICAL BREAST CANCER | 2024年 / 24卷 / 04期

关键词：

1ST-LINE TREATMENT; BEVACIZUMAB; PACLITAXEL; INHIBITOR; EFFICACY; CHEMOTHERAPY; KINASE; SAFETY; TRIAL;

D O I：

10.1016/j.clbc.2024.01.018

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：195 / 202

页数：8

共 50 条

[11] Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Li, Junjie
Yu, Keda
Pang, Da
Wang, Changqin
Jiang, Jun
Yang, Suisheng
Liu, Yunjiang
Fu, Peifen
Sheng, Yuan
Zhang, Guojun
Cao, Yali
He, Qi
Cui, Shude
Wang, Xijing
Ren, Guosheng
Li, Xinzheng
Yu, Shiyou
Liu, Pengxi
Qu, Xiang
Tang, Jinhai
Wang, Ouchen
Fan, Zhimin
Jiang, Guoqin
Zhang, Jin
Wang, Jiandong
Zhang, Hongwei
Wang, Shui
Zhang, Jianguo
Jin, Feng
Rao, Nanyan
Ma, Binlin
He, Pingqing
Xu, Binghe
Zhuang, Zhigang
Wang, Jianfeng
Sun, Qiang
Guo, Xiaofeng
Mo, Miao
Shao, Zhimin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1774 - +
[12] Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial
Shi, Qiyun
Qi, Xiaowei
Tang, Peng
Fan, Linjun
Chen, Li
Wang, Shushu
Zhang, Guozhi
Wang, Mengyuan
Che, Hongying
Lv, Pengwei
Chen, Dejie
Hu, Jinhui
Li, Qiuyun
Zhang, Yanwu
Yu, Qiao
Yang, Kunxian
Zhong, Yuan
Chen, Chuang
Zhou, Zemin
Qian, Liyuan
Zhang, Jingwei
Ma, Mingde
Sun, Yi
Liu, Jiangbo
Zhang, Yi
Jiang, Jun
CANCER RESEARCH, 2023, 83 (05)
[13] Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer
Wirth, Lori J.
Brose, Marcia S.
Sherman, Eric J.
Licitra, Lisa
Schlumberger, Martin
Sherman, Steven, I
Bible, Keith C.
Robinson, Bruce
Rodien, Patrice
Godbert, Yann
De La Fouchardiere, Christelle
Newbold, Kate
Nutting, Christopher
Misir, Soamnauth
Xie, Ran
Almonte, Ana
Ye, Weifei
Cabanillas, Maria E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (21) : 2359 - +
[14] Phase II study of combined docetaxel, epirubicin, and cyclophosphamide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer in a single institution
Yao, X.
Hosenpud, J. R.
Chitambar, C. R.
Charlson, J. A.
Cheng, Y.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[15] A Phase II Study of Concurrent Docetaxel, Epirubicin and Cyclophosphamide as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer
Yao, Xin
Hosenpud, Janet
Chitambar, Christopher R.
Charlson, John
Cheng, Yee Chung
JOURNAL OF CANCER, 2012, 3 : 145 - 151
[16] Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial
Li, Junjie
Yu, Keda
Pang, Da
Wang, Changqin
Jiang, Jun
Yang, Suisheng
Liu, Yunjiang
Fu, Peifen
Sheng, Yuan
Zhang, Guojun
Cao, Yali
He, Qi
Cui, Shude
Wang, Xijing
Ren, Guosheng
Li, Xinzheng
Yu, Shiyou
Liu, Pengxi
Tang, Jinhai
Wang, Ouchen
Fan, Zhimin
Jiang, Guoqin
Zhang, Jin
Shao, Zhimin
CANCER RESEARCH, 2020, 80 (04)
[17] A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
Hasegawa, Hirotaka
Shitara, Kohei
Takiguchi, Shuji
Takiguchi, Noriaki
Ito, Seiji
Kochi, Mitsugu
Horinouchi, Hidehito
Kinoshita, Takahiro
Yoshikawa, Takaki
Muro, Kei
Nishikawa, Hiroyoshi
Suna, Hideaki
Kodera, Yasuhiro
GASTRIC CANCER, 2022, 25 (03) : 619 - 628
[18] Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin for early triple-negative breast cancer: A singlearm, open-label, phase II study
Wang, C.
Liu, Z.
Chen, X.
Qiao, J.
Li, L.
Lu, Z.
Sun, X.
ANNALS OF ONCOLOGY, 2021, 32 : S436 - S436
[19] A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer
Hirotaka Hasegawa
Kohei Shitara
Shuji Takiguchi
Noriaki Takiguchi
Seiji Ito
Mitsugu Kochi
Hidehito Horinouchi
Takahiro Kinoshita
Takaki Yoshikawa
Kei Muro
Hiroyoshi Nishikawa
Hideaki Suna
Yasuhiro Kodera
Gastric Cancer, 2022, 25 : 619 - 628
[20] Tenacity: A phase 2, multicenter, open-label, single-arm study of AL101 monotherapy in patients with notch-activated triple negative breast cancer
Traina, Tiffany A.
Cobain, Erin F.
Evron, Ella
Duksin, Chen
Gordon, Gary
CANCER RESEARCH, 2021, 81 (04)

← 1 2 3 4 5 →